• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Early monoclonal antibody treatment associated with a reduced risk of COVID-19 hospitalization

byDavid XiangandKiera Liblik
April 17, 2023
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this propensity score–matched cohort study, early treatment with monoclonal antibodies for outpatients with coronavirus disease 2019 (COVID-19) was associated with a lower risk of hospitalization.

2. Early treatment with monoclonal antibodies for COVID-19 showed similar effects across COVID-19 variants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Monoclonal antibody treatment has been authorized for use by the Food and Drug Administration for patients diagnosed with mild to moderate COVID-19 and at risk for progression to severe disease. However, there is a gap in knowledge as to understanding the efficacy of individual monoclonal antibody products as new COVID-19 variants emerge. There are also limited, large-scale observational clinical data for the use of monoclonal antibody products in infected patients. Overall, this study found that early treatment with five different monoclonal antibody products was consistently associated with a lower risk for hospitalization or death over nearly two years. This study was limited by being unable to determine symptom severity, which means that many nontreated patients may have been asymptomatic and, therefore, at low risk for hospitalization. Furthermore, vaccination status was only available in a minority of all patients, and treatment with other outpatient therapies for COVID-19 was not captured. Nevertheless, these study’s findings are significant, as they demonstrate that early treatment of mAb for COVID-19 in outpatients was significantly associated with a lower risk for hospitalization or death over a two-year period.

Click to read the study in AIM

Relevant Reading: Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy

RELATED REPORTS

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

Second-line TAF-based ART improves viral suppression in pediatric HIV

Midlife weight loss is associated with decreased risk of mortality and chronic disease

In-Depth [propensity score–matched cohort study]: This cohort study included patients in the University of Pittsburgh Medical Center health system extracted from December 2020 to August 2022. Patients who were aged 12 years or older, had at least one Emergency Use Authorization-eligible risk factor for progression to severe disease, were not pregnant, were not in the emergency department (ED) or hospital on the index date, and had near-complete covariate data for analysis were eligible for the study. Patients who received tixagevimab–cilgavimab (Evusheld [AstraZeneca]; preexposure prophylaxis for prevention of COVID-19) before or within 28 days of the index date were excluded from the study. The primary outcome measured was the risk of hospitalization or death at 28 days. Outcomes in the primary analysis were assessed via propensity scores from a logistic regression model fit with classification into the monoclonal antibody treatment group. Based on the primary analysis, the risk for hospitalization or death at 28 days was 4.6% in 2,571 treated patients and 7.6% in 5,135 nontreated control patients (risk ratio, 0.61; 95% Confidence Interval, 0.50 to 0.74). The corresponding risk ratios for one and three-day treatment grace periods were 0.59 and 0.49, respectively. In the secondary subgroup analyses, for patients with presumed alpha and delta variants, the patients who received monoclonal antibodies had risk ratios of 0.55 and 0.53, respectively, compared with 0.71 for the omicron variant period. In summary, this study demonstrates that early monoclonal antibody treatment for outpatient COVID-19 management is significantly associated with a lower risk of hospitalization or death.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cilgavimabCoronavirus disease 2019COVID-19Food and Drug Administrationinfectious diseaseMonoclonal antibody treatmentpublic healthtixagevimab
Previous Post

Self-reported functional impairment and frailty improve the prediction of healthcare expenditures

Next Post

Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Chronic Disease

Midlife weight loss is associated with decreased risk of mortality and chronic disease

June 3, 2025
Chronic Disease

Incidence and prevalence of dementia among US Medicare beneficiaries between 2015 – 2021

May 31, 2025
Next Post
Elective colectomy associated with improved survival in ulcerative colitis

Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis

Medical vaccine exemptions increase after elimination of nonmedical exemptions

Prior BCG vaccination may be protective against severe COVID

Mediterranean diet may reduce age-related neurocognitive decline

Nut consumption may be inversely associated with frailty in older women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large language models show potential to provide feedback on research papers on a large-scale
  • #VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
  • Fecal microbiota transplantation may be more effective than vancomycin in treating primary C. difficile infection
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.